As an expert tuned into the latest headlines impacting our industry, you’ve likely heard the big news: Many biosimilars for AbbVie’s blockbuster anti-inflammatory drug, Humira, are coming to market in 2023!
The biotech firms behind these new drugs are rejoicing as they not-so-patiently wait to get their FDA-approved Humira biosimilars to market. Should you be celebrating, too? Could biosimilars hold the key to curbing rising Rx costs? How can you navigate the PBM complexities surrounding biosimilars?
Join our panel of industry thought leaders for a crash course on biosimilars as they explore what this groundbreaking news could mean for the TPA community and the clients you serve!
About the Speakers:
|
Kevin Kobielski
President, AlignRx
|
|
Kevin’s experience, vision and fundamental understanding into the complexity of how pharmacy benefits work, helps ensure AlignRx clients optimize their pharmacy spend and lower costs. Kevin and his team focus on leveraging AlignRx’s expertise
and empowering clients with knowledge and strategies to select the right pharmacy benefit solutions. With unique experience as a senior executive in healthcare, Kevin knows how pharmacy benefits work from every angle. That vision gives
him a fresh approach to solving the problems that hinder profitability and flexibility for TPAs, brokers and health plans.
|
|
Beckie Fenrick, Pharm D
Chief Pharmacy Officer, AlignRx
|
|
Beckie helps patients, providers, health plans, employers and PBMs realize better outcomes from their pharmacy experiences. Her track record as a pharmacy thought leader and change agent for 25 years helps her understand problems, see opportunities
and rethink better ways for AlignRx customers to handle rebates, ASO business and overall pharmacy operations. As Chief Pharmacy Officer at AlignRx, she leverages her knowledge from advising major U.S. companies on the right ways to structure,
manage and administer their pharmacy benefits.
|
Hosted By:
Print Page